^
    16d
    A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (clinicaltrials.gov)
    P1, N=40, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting --> Completed | N=90 --> 40 | Trial completion date: Dec 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date
    |
    AL-034
    4ms
    A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov)
    P1/2, N=30, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial • Metastases
    |
    Focus V (anlotinib) • AL-034
    5ms
    A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer. (PubMed, Int Immunopharmacol)
    Furthermore, combining TQ-A3334 with anti-PD-L1 treatment exceeded tumor control, with a further increase in CD8+ TIL frequency compared to monotherapy. These findings suggest that TQ-A3334 can mobilize innate immunity and promote T cell recruitment into the tumor microenvironment; a combination of TQ-A3334 and anti-PD-L1 antibodies can intensify the sensitivity of tumors to anti-PD-L1 therapy, which demonstrates significant potential for treating poorly immune-infiltrated lung cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IFNA1 (Interferon Alpha 1)
    |
    AL-034
    11ms
    A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (clinicaltrials.gov)
    P1, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AL-034
    11ms
    A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    AL-034
    over4years
    A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Jul 2020
    Clinical • Trial initiation date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Focus V (anlotinib) • AL-034
    over4years
    A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Focus V (anlotinib) • AL-034